Navitoclax (ABT-263) Plus Fludarabine/Cyclophosphamide/Rituximab (FCR) or Bendamustine/Rituximab (BR): A Phase 1 Study in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

被引：0
|
作者：
Kipps, Thomas J. [1 ]
Swinnen, Lode J. [2 ]
Wierda, William G. [3 ]
Jones, Jeffrey Alan [4 ]
Coutre, Steven E. [5 ,6 ,7 ]
Smith, Mitchell R. [8 ]
Yang, Jainning [9 ]
Cui, Yue [9 ]
Busman, Todd [9 ]
Enschede, Sari [9 ]
Humerickhouse, Rod [9 ]
机构：
[1] Univ Calif San Diego, La Jolla, CA 92093 USA
[2] Johns Hopkins Univ, Sch Med, Sydney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
[4] Ohio State Univ, Columbus, OH 43210 USA
[5] Stanford Univ, Sch Med, Div Hematol, Stanford, CA 94305 USA
[6] Stanford Univ, Sch Med, Div Oncol, Stanford, CA 94305 USA
[7] Stanford Univ, Sch Med, Stanford Canc Ctr, Stanford, CA 94305 USA
[8] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA
[9] Abbott Labs, Abbott Pk, IL 60064 USA
来源：
BLOOD | 2011年 / 118卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1669 / 1669
页数：1
相关论文
共 50 条
  • [31] Long-Term Follow-up of a Phase 1 Trial of Idelalisib (ZYDELIG®) in Combination with Bendamustine (B), Bendamustine/Rituximab (BR), Fludarabine (F), Chlorambucil (Chl), or Chlorambucil/Rituximab (ChlR) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
    Barrientos, Jacqueline C.
    Coutre, Steven E.
    de Vos, Sven
    Wagner-Johnston, Nina D.
    Flinn, Ian W.
    Sharman, Jeff P.
    Schreeder, Marshall T.
    Boyd, Thomas E.
    Rai, Kanti R.
    Leonard, John P.
    Kim, Yeonhee
    Viggiano, Anthony
    Jahn, Thomas M.
    Furman, Richard R.
    BLOOD, 2014, 124 (21)
  • [32] Acalabrutinib vs Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia: ASCEND Final Results
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (01) : 12 - 13
  • [33] Comparison of fludarabine (F), cyclophosphamide (C), and rituximab (R) versus FCR plus bevacizumab (B) in relapse chronic lymphocytic leukemia (CLL)
    Lee, Hun Ju
    Wierda, William G.
    Ferrajoli, Alessandra
    Burger, Jan Andreas
    Trinh, Long
    Lerner, Susan
    Keating, Michael J.
    O'Brien, Susan Mary
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [34] Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia: ASCEND Final Results
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (09) : 2 - 4
  • [35] The outcome of chronic lymphocytic leukemia patients who relapsed after fludarabine, cyclophosphamide, and rituximab
    Panovska, Anna
    Smolej, Lukas
    Lysak, Daniel
    Brychtova, Yvona
    Simkovic, Martin
    Motyckova, Monika
    Vodarek, Pavel
    Lindtnerova, Michaela
    Trbusek, Martin
    Malcikova, Jitka
    Pospisilova, Sarka
    Mayer, Jiri
    Doubek, Michael
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2013, 90 (06) : 479 - 485
  • [36] Long-Term Results of Chemoimmunotherapy With Fludarabine, Cyclophosphamide, and Rituximab for Patients With Relapsed and Refractory Chronic Lymphocytic Leukemia
    Badoux, Xavier
    Keating, Michael J.
    Ferrajoli, Alessandra
    Lerner, Susan
    Wang, Xuemei
    O'Brien, Susan
    Wierda, William G.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2010, 10 (03): : E35 - E35
  • [37] Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia
    Robak, Tadeusz
    Lech-Maranda, Ewa
    Robak, Pawel
    EXPERT REVIEW OF ANTICANCER THERAPY, 2010, 10 (10) : 1529 - 1543
  • [38] ASCEND Phase 3 study of acalabrutinib versus investigator's choice of rituximab plus idelalisib (IdR) or bendamustine (BR) in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)
    Ghia, Paolo
    Pluta, Andrzej
    Wach, Malgorzata
    Lysak, Daniel
    Kozak, Tomas
    Simkovic, Martin
    Kaplan, Polina
    Kraychok, Iryna
    Illes, Arpad
    de la Serna, Javier
    Dolan, Sean
    Campbell, Philip
    Musuraca, Gerardo
    Jacob, Abe
    Avery, E. J.
    Lee, Jae Hoon
    Liang, Wei
    Patel, Priti
    Quah, Cheng
    Jurczak, Wojciech
    LEUKEMIA & LYMPHOMA, 2020, 61 : 235 - 237
  • [39] Ascend Phase 3 Study of Acalabrutinib vs Investigator's Choice of Rituximab Plus Idelalisib (IDR) or Bendamustine (BR) in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)
    Hebart, Holger
    Ghia, Paolo
    Jurczak, Wojciech
    Pluta, Andrzej
    Wach, Malgorzata
    Lysak, Daniel
    Kozak, Tomas
    Simkovic, Martin
    Kaplan, Polina
    Kryachok, Irina
    Illes, Arpad
    De la Serna, Javier
    Dolan, Sean
    Campbell, Philip
    Musuraca, Gerardo
    Jacob, Abraham
    Avery, Eric
    Patel, Priti
    Quah, Cheng
    Liang, Wei
    Lee, Jae Hoon
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 128 - 129
  • [40] Idelalisib in Combination With Rituximab or Bendamustine or Both in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia
    Coutre, Steven E.
    Flinn, Ian W.
    de Vos, Sven
    Barrientos, Jacqueline C.
    Schreeder, Marshall T.
    Wagner-Johnson, Nina D.
    Sharman, Jeff P.
    Boyd, Thomas E.
    Fowler, Nathan
    Dreiling, Lyndah
    Kim, Yeonhee
    Mitra, Siddhartha
    Rai, Kanti
    Leonard, John P.
    Furman, Richard R.
    HEMASPHERE, 2018, 2 (03):
12345